LONDON, Oct 12: – AstraZeneca has signed a deal to co-promote Johnson & Johnson’s novel prostate cancer medicine in Japan, giving the British company a new drug revenue stream and bolstering its Japanese presence. Financial terms of the agreement, announced by AstraZeneca on Friday, were not disclosed.
(agencies)
Follow our WhatsApp channel